IAG and Takeda Partner to Augment Clinical Decision Making with AI Driven Methodology for Ulcerative Colitis Histopathological Image Analysis
Image Analysis Group today announced a partnership in the field of ulcerative colitis (UC) histopathological image analysis with Takeda Pharmaceutical Company Limited.
The objective of the collaboration is to develop and validate an artificial intelligence (AI) powered tool that will potentially allow gastroenterologists to effectively incorporate histology (the study of the microscopic structure of tissues) in their real-life assessment of people suffering from UC.
In this collaboration, the parties will utilize an AI-driven approach to augment clinical decision making when assessing disease activity and the efficacy of treatments in UC. The parties will focus on the validation of the use of deep learning models and the use of IAG’s methodologies and platform DYNAMIKA in automating the assessment of UC histopathological images.
With support from the world’s leading clinical research opinion leaders and experienced pathologists, IAG will develop a seamless workflow to process and analyze the imaging data and provide expertise in using deep learning and AI and apply these models to the imaging data analysis.
Collaboration statements
Prof. Laurent Peyrin-Biroulet, Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, the scientific lead on this project, said “The success of patient treatment with novel therapeutic agents highly depends on the efficient use of modern technologies and data-centric development approaches. In such a critical area as IBD, our patients will no doubt will benefit from the use of Artificial Intelligence to augment clinical decisions.“
“With results from recent clinical trials and emerging concepts of response to treatment such as disease clearence, there is a growing need to look at the disease through a different lens and ideally in a combined and holistic way. In real life, there are barriers in terms of access to trained IBD Pathologists. With its focus on automated quantitative imaging-driven analytics, this collaboration is a step towards putting assessment tools in the hands of practicing gastroenterologists, which will ultimately benefit patients“, added Dr. Andrea Stancati M.D., Vice President, Global Medical Franchise Head, Gastroenterology at Takeda
“We believe in demystifying AI and making it truly useful in the clinical decision making and clinical research”, said Dr. Olga Kubassova, CEO if IAG, “IAG is uniquely positioned to provide tools which could be a game-changer, particularly for the development and use of advanced therapies in complex areas such as IBD, ultimately supporting the goal of getting the right treatment to the right patients at the right time.”
Image Analysis Group (IAG)
IAG, a pioneering imaging Clinical Research Organization (iCRO), seamlessly blends medical acumen, operational excellence, and cutting-edge AI to accelerate drug development. Since 2007, we’ve been the trusted partner for global biotech and pharma, expertly managing imaging across Phase I-III trials and real-world evidence studies in diverse therapeutic areas.
Our award-winning DYNAMIKA platform ensures unparalleled data integrity, while our innovative approach consistently unlocks and amplifies the value of novel therapies.
Partner with IAG to transform your clinical trials and maximize your therapeutic asset’s market potential.